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renovascular hypertensionHypertension is one of the most common chronic illnesses,
along with diabetes mellitus, that the world faces. Numerous
previous studies have shown that hypertension is a signiﬁcant
risk factor for stroke, myocardial infarction, heart failure, arterial
ﬁbrillation, aortic dissection, and peripheral arterial diseases
[1,2]. Even though the development of effective pharmacological
strategies for blood pressure control is a notable and worthwhile
medical achievement of the 20th century, hypertension remains
a leading cause of death worldwide and one of the world's
greatest public health problems [3].
A large body of evidence has shown that hypertensive
patients are characterized by endothelial dysfunction and
a spectrum of pathophysiological changes in the vascular
endothelium at the macro- and microcirculation levels, which
result in a loss of vascular homeostasis [4]. The dysfunctional
endothelium gives rise to cardiovascular events. In addition,
the degree of endothelial dysfunction is correlated signiﬁ-
cantly with cardiovascular outcomes [5]. Various molecules
mediating vasoconstriction, vasodilation, inﬂammation, and
thrombosis are involved in the development of endothelial
dysfunction. However, the 1998 Nobel Prize-winner Robert
Furchgott proved in a pioneering report that endothelial dys-
function consists primarily of dysregulation in vasodilation [6].
Nitric oxide (NO) is a primary mediator of endothelium-
dependent vasodilatation [7].
Nitric oxide is produced in the blood vessel wall through
the transformation process of L-arginine into citrulline by the
activity of the constitutive enzyme endothelial NO synthase.
The production of NO is inﬂuenced by several agonists such as
acetylcholine, bradykinin, substance P, serotonin, and other
ligands acting on speciﬁc endothelial receptors and inﬂuenced
by mechanical forces such as shear stress [7]. Blood vessels are
physiologically maintained in a dilated state that is mediated
by a stable level of NO. However, in pathological conditions,
the balance of NO is jeopardized by an excessive level of
reactive oxygen species (ROS), which leads to a breakdown of
NO [8].
Several stimuli such as proinﬂammatory tumor necrosis
factor-α, asymmetrical dimethyl-arginine, angiotensin II, and
shear stress—all of which are associated with the development
of hypertension—induce endothelial dysfunction [9]. However,
the molecular mechanisms underlying the impaired endothe-
lial modulation by these stimuli are not extensively clariﬁed.132/$ - see front matter & 2014. The Korean Society of Nephrology. Pub
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
dx.doi.org/10.1016/j.krcp.2014.02.003Miyagawa et al [10] recently showed that abnormal endothe-
lial modulation of vascular contraction in the femoral arteries
of spontaneously hypertensive rats (SHR) was mostly the
result of increased production of superoxide anions by nicoti-
namide adeninedinucleotide/nicotinamide adenine dinuc-
leotide phosphate (NADH/NADPH) oxidase. Angiotensin II
type 1 receptor blockade with CV-11974 (an active form of
the angiotensin II type 1 receptor antagonist candesartan)
moreover had no effect on norepinephrine-induced contrac-
tion in SHR arteries, which suggested that the angiotensin II
type 1 receptor was not involved in the activation of NADH/
NADPH oxidase under their experimental conditions. Because
the pathophysiological mechanism of hypertension in the SHR
model is not fully understood, it is not easy to dissect the effect
of individual stimulus on endothelial function with this animal
model of hypertension [11].
In this issue of Kidney Research and Clinical Practice, Choi
et al [12] try to explore further the possible mechanisms
underlying impaired endothelial modulation by using two-
kidney one clip (2K1C) hypertension rats as an animal model
of chronic renovascular hypertension in humans. After remov-
ing the endothelium or treating specimens with Nω-nitro-L-
arginine methylester (L-NAME, which inhibits the endogenous
production of NO from L-arginine), norepinephrine-induced
contraction was signiﬁcantly more augmented in sham-
operated control rats (CON) than in 2K1C rats. Furthermore,
the amount of NO released during norepinephrine-induced
contraction was not different between arteries obtained from
the CON rats and the 2K1C rats. Based on these ﬁndings, they
suggest that the production of endothelium-derived NO is
impaired because of increased inactivation of NO rather than
because of decreased NO production in 2K1C hypertension.
Choi et al further carefully explore the pathophysiology of
impaired endothelium-derived NO in 2K1C rats by measuring
the contractile capacity of aorta specimens from these rats.
They demonstrated that norepinephrine-induced contraction
was signiﬁcantly suppressed by vitamin C, diphenyleneiodo-
nium, apocynin, or inhibitors of NADH/NADPH oxidase in
aortic rings with intact endothelium from 2K1C rats, but not
from CON rats. This indicates that the production of ROS is
most likely involved in endothelial dysfunction in 2K1C
hypertension. In addition, allopurinol had no effect on the
contraction of aortic rings from 2K1C rats. This supports thelished by Elsevier. This is an open access article under the CC BY-NC-ND
Editorial / Kidney Res Clin Pract 33 (2014) 1–22notion that ROS production in this rat model is inﬂuenced by
NADH/NADPH oxidase rather than by xanthine oxidase. The
authors collectively propose that endothelial dysfunction in an
animal model of chronic renovascular hypertension may be
because of inactivation of NO resulting from increased ROS
production by NADH/NADPH oxidase.
The study by Choi et al is interesting because it provides
insights on the possible underlying mechanism of angiotensin II-
induced endothelial dysfunction in hypertension. The renin–
angiotensin system is activated in renovascular hypertension,
which results in increased circulating angiotensin II levels. Based
on the ﬁndings of Choi et al, increased circulating angiotensin II
may activate NADH/NADPH oxidase and enhance ROS production
in the vascular endothelium. Previous ﬁndings from in vitro
experiments showing that angiotensin II stimulates the generation
of superoxide anion radicals in cultured vascular smooth muscle
cells also support this notion [13]. However, it should be recog-
nized that even though the levels of circulating angiotensin II are
increased in 2K1C rat models, the exact mechanism for high
blood pressure is still unclear. The authors moreover did not
examine the direct effect of angiotensin II receptor blockade on
norepinephrine-induced vascular contraction. Therefore, further
investigations are needed to elucidate the exact mechanism of
angiotensin II-induced endothelial dysfunction.
In summary, the study ﬁndings of Choi et al provide a
proper description of the source of superoxide production, and
they showed that oxidative stress is a key player related to
endothelial dysfunction in chronic renovascular hypertension.
In spite of the aforementioned limitations, the results are
intriguing and allow us to understand further the pathophy-
siology of vascular endothelial dysfunction in hypertension.
Judging by the given evidence, nevertheless, it is unclear
whether oxidative stress is the capo or just an associate of
endothelial dysfunction.Conﬂicts of interest
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